Accord BioPharma’s Biosimilar IMULDOSA gains USFDA approval for treatment of chronic inflammatory…
Intas Pharmaceuticals acquired exclusive commercialisation rights to DMB-3115 through a license agreement in 2021
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.